Actively Recruiting

Phase Not Applicable
Age: 55Years +
All Genders
Healthy Volunteers
NCT04692441

Apolipoprotein E (APOE) Genotype Effects on Triglycerides and Blood Flow in the Human Brain

Led by University of Washington · Updated on 2024-05-24

90

Participants Needed

1

Research Sites

243 weeks

Total Duration

On this page

Sponsors

U

University of Washington

Lead Sponsor

N

National Institute on Aging (NIA)

Collaborating Sponsor

AI-Summary

What this Trial Is About

High fat feeding (HFF) increases the risk of Alzheimer's disease (AD) but individuals who carry the AD risk gene E4 paradoxically improve after acute HFF. The investigators propose to further study this phenomenon with a clinical study to assess cerebral blood flow which can be measured by a technique called arterial spin labeling (ASL) on an MRI and is tightly related to brain metabolism.

CONDITIONS

Official Title

Apolipoprotein E (APOE) Genotype Effects on Triglycerides and Blood Flow in the Human Brain

Who Can Participate

Age: 55Years +
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Aged 55 or older at the date of the screening visit
  • Equal representation of APOE E4 carriers and non-carriers
  • Strive for equal numbers of men and women; women must be post-menopausal for at least 1 year or have a medical equivalent such as hysterectomy
  • Able to read and understand English
  • Able to cognitively and physically give informed consent
  • Able to undergo an MRI and ingest dairy products
Not Eligible

You will not qualify if you...

  • Diabetes requiring medication, including type 1 or type 2 diabetes treated with oral drugs or insulin; diet-controlled diabetes or pre-diabetes allowed
  • Taking medication for hypertension, unless safe to stop for 2 weeks before the MRI visit as approved by primary care provider
  • Significant lipid abnormalities requiring statin, bile acid resins, fibrates, or high dose niacin; must be willing to stop these medications 4 weeks before screening if not on secondary prevention
  • Known dementia, use of dementia medications, or other neurological diseases affecting cognition like recent stroke or advanced Parkinson's
  • Active untreated major depression, psychosis, mania, or active alcohol or drug abuse disorder
  • Other serious illnesses that would make attending visits or tests difficult, such as unstable angina, severe lung or heart disease, active liver or kidney disease with cognitive symptoms, or active cancer undergoing treatment
  • Major digestive disorders affecting fat absorption or allergies/intolerance to milk or dairy
  • Contraindications to MRI such as incompatible metal implants or inability to lie still or flat for the MRI duration

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University of Washington Medical Center

Seattle, Washington, United States, 98195

Actively Recruiting

Loading map...

Research Team

A

Angela J Hanson, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

BASIC_SCIENCE

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Apolipoprotein E (APOE) Genotype Effects on Triglycerides and Blood Flow in the Human Brain | DecenTrialz